Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Anaadriana Zakarija, MD, Hau C. Kwaan, MD PhD, Nicholas Banderanko, MD, Dilip K. Pandey, MD PhD, John F. Cursio, MS, Ivy M. Weiss, BA, Thanh Ha Luu, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD PhD, Thomas J. Raife, MD, Ravindra Sarode, MD, Charles L. Bennett, MD PhD MPP

Blood (2007) 110 (11): 1320.

https://doi.org/10.1182/blood.V110.11.1320.1320

Published: 2007

Journal Articles

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Charles L. Bennett, MD, PhD, MPP, Thanh Ha Luu, BA, Anaadriana Zakarija, MD, Hau C. Kwaan, MD, PhD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, John F. Cursio, MS, June M. McKoy, MD, JD, MPH, Charlie Buffie, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD, Ravindra Sarode, MD, X. Long Zheng, MD, PhD, Thomas J. Raife, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Gail A. Rock, MD, PhD

Blood (2007) 110 (11): 2088.

https://doi.org/10.1182/blood.V110.11.2088.2088

Published: 2007

Journal Articles

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Elizabeth A. Richey, BA, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, MD, PhD, Anaadriana Zakarija, MD, MSCI, Nicholas Banderanko, MD, Dilip K. Pandey, MD, PhD, June M. McKoy, MD, JD, MPH, Paul R. Yarnold, PhD, Dennis W. Raisch, PhD, Jeffrey L. Winters, MD, Thomas J. Raife, MD, John F. Cursio, MS, Matthew J. Fisher, Thomas L. Ortel, MD, PhD, Martin S. Tallman, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Joel L. Moake, MD

Blood (2007) 110 (11): 2089.

https://doi.org/10.1182/blood.V110.11.2089.2089

Published: 2007

Journal Articles

ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).

H.C. Kwaan, MD, PhD, June M. McKoy, MD, MPH, JD, Kathryn R. McCaffrey, BA, Paul R. Yarold, PhD, Benjamin Kim, MD, Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, MD, PhD, James N. George, MD, X. Long Zheng, MD, PhD, Kenneth R. Carson, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2005) 106 (11): 60.

https://doi.org/10.1182/blood.V106.11.60.60

Published: 2005

Journal Articles

Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, Hau Kwaan, MD, PhD, Kathryn McCaffrey, BA, Denise Finley, BA, Ken Carson, MD, Paul Yarnold, PhD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 855.

https://doi.org/10.1182/blood.V104.11.855.855

Published: 2004

Journal Articles

Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?.

Benjamin Kim, MD, Kenneth R. Carson, MD, Kathryn McCaffrey, BA, Denise Finley, Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, Dennis W. Raisch, PhD, Hau C. Kwaan, MD, PhD, Paul R. Yarnold, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2004) 104 (11): 860.

https://doi.org/10.1182/blood.V104.11.860.860

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).

Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?.

Email alerts

ASH Publications

American Society of Hematology

Update search

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).

Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only